An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials

Seung Ho Kang, Chul W. Ahn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.

Original languageEnglish
Pages (from-to)865-873
Number of pages9
JournalDrug Information Journal
Volume36
Issue number4
DOIs
Publication statusPublished - 2002 Jan 1

Fingerprint

Clinical Trials, Phase I
Maximum Tolerated Dose
Toxicity
Neoplasms
Logistics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology (nursing)
  • Drug guides
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Cite this

@article{66bea0e5bb8644978da8be9d6e5e4225,
title = "An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials",
abstract = "The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.",
author = "Kang, {Seung Ho} and Ahn, {Chul W.}",
year = "2002",
month = "1",
day = "1",
doi = "10.1177/009286150203600415",
language = "English",
volume = "36",
pages = "865--873",
journal = "Drug Information Journal",
issn = "0092-8615",
publisher = "Drug Information Association",
number = "4",

}

An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials. / Kang, Seung Ho; Ahn, Chul W.

In: Drug Information Journal, Vol. 36, No. 4, 01.01.2002, p. 865-873.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An investigation of the traditional algorithm-based designs for phase 1 cancer clinical trials

AU - Kang, Seung Ho

AU - Ahn, Chul W.

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.

AB - The primary aim of a phase 1 cancer clinical trial is to determine the maximum tolerated dose of a new drug. Although the continual reassessment method is shown to have better operating characteristics than traditional designs, traditional designs are still widely used in practice. Kang and Ahn (1) developed an algorithm to compute the exact distribution of the maximum tolerated dose (MTD) in traditional designs with dose deescalation and investigated the expected toxicity rate at the MTD with the algorithm. In this paper, using the exact formulae derived by Lin and Shih (2), we study the expected toxicity rate at the MTD and the expected number of patients with toxicity and patients required when the hyperbolic tangent and the logistic functions are used as the unknown dose-toxicity curves. We consider the expected toxicity rate both without and with dose deescalation. No further study was done before in cases where dose level zero is chosen as the MTD. Since, in real practice, dose levels are lowered for adjustment and a new trial is conducted when dose level zero is decided as the MTD, we also incorporate this dose adjustment.

UR - http://www.scopus.com/inward/record.url?scp=0036975813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036975813&partnerID=8YFLogxK

U2 - 10.1177/009286150203600415

DO - 10.1177/009286150203600415

M3 - Article

AN - SCOPUS:0036975813

VL - 36

SP - 865

EP - 873

JO - Drug Information Journal

JF - Drug Information Journal

SN - 0092-8615

IS - 4

ER -